Literature DB >> 10822381

Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers.

K Yanagisawa1, K Uchida, M Nagatake, A Masuda, M Sugiyama, T Saito, K Yamaki, T Takahashi, H Osada.   

Abstract

Smad family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities. The loss of sensitivity to TGF-beta is frequent in human lung cancers and inactivation of Smad family members are thought to play important roles in disruption of TGF-beta signaling. In the study presented here, we characterized the biological and biochemical functions of six Smad2 and Smad4 mutants, which we previously identified in human lung cancers. All mutant Smad2 and Smad4 were in fact found to be defective in transmitting growth inhibitory signals originating from TGF-beta and incapable of activating Smad/hFAST-1-mediated transcription. Transcriptional activation of plasminogen activator inhibitor type 1 (PAI-1) was impaired in four of the six mutants due to the defects in homo- and/or hetero-oligomerization with wild-type Smads. In contrast, the remaining two Smad mutants showed a modest reduction in the PAI-1 transcriptional activation and apparently retained the ability to oligomerize with wild-type Smads. Significant loss of growth inhibition and Smad/hFAST-1-mediated transcriptional activation by all of the six mutants suggested that Smad mutants are indeed functionally impaired Smad mutations and may play a role in lung tumorigenesis. Moreover, the present findings suggest that in addition to the impairment in the homo- and/or hetero-oligomerization, there may be an alternative mechanism producing disruption of TGF-beta signaling, involving hFAST-1-or possibly other transcriptional cofactor(s)-mediated transcriptional activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822381     DOI: 10.1038/sj.onc.1203591

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.

Authors:  Gemma Armengol; Virinder Kaur Sarhadi; Mikko Rönty; Milja Tikkanen; Aija Knuuttila; Sakari Knuutila
Journal:  Lung       Date:  2015-02-14       Impact factor: 2.584

2.  MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.

Authors:  Ri Cui; Wei Meng; Hui-Lung Sun; Taewan Kim; Zhenqing Ye; Matteo Fassan; Young-Jun Jeon; Bin Li; Caterina Vicentini; Yong Peng; Tae Jin Lee; Zhenghua Luo; Lan Liu; Dongyuan Xu; Esmerina Tili; Victor Jin; Justin Middleton; Arnab Chakravarti; Tim Lautenschlaeger; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-17       Impact factor: 11.205

3.  Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.

Authors:  Yanchun Ma; Kun Chen; Zhenhua Yang; Ming Guan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

Review 4.  The tale of transforming growth factor-beta (TGFbeta) signaling: a soigné enigma.

Authors:  Arindam Chaudhury; Philip H Howe
Journal:  IUBMB Life       Date:  2009-10       Impact factor: 3.885

Review 5.  Roles of Smad3 in TGF-beta signaling during carcinogenesis.

Authors:  Caroline Millet; Ying E Zhang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2007       Impact factor: 1.807

6.  Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1.

Authors:  Kimberly A Brown; Amy-Joan L Ham; Cara N Clark; Nahum Meller; Brian K Law; Anna Chytil; Nikki Cheng; Jennifer A Pietenpol; Harold L Moses
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

7.  SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.

Authors:  Yue Wang; Qianqian Xue; Qiang Zheng; Yan Jin; Xuxia Shen; Mu Yang; Xiaoyan Zhou; Yuan Li
Journal:  Lab Invest       Date:  2020-12-10       Impact factor: 5.662

8.  Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro.

Authors:  Kimberly A Brown; Mary E Aakre; Agnieska E Gorska; James O Price; Sakina E Eltom; Jennifer A Pietenpol; Harold L Moses
Journal:  Breast Cancer Res       Date:  2004-03-17       Impact factor: 6.466

9.  Transforming Growth Factor-beta2 protects the small intestine during methotrexate treatment in rats possibly by reducing stem cell cycling.

Authors:  B van't Land; H P Meijer; J Frerichs; M Koetsier; D Jager; R L Smeets; L M'Rabet; M Hoijer
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

10.  Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B.

Authors:  Shinichiro Kato; Yoshihiro Hayakawa; Hiroaki Sakurai; Ikuo Saiki; Satoru Yokoyama
Journal:  Cancer Sci       Date:  2014-01-29       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.